The Exciting Future for Scleroderma
This article reviews recent progress in understanding how fibrosis becomes profibrotic and how the immune system, vascular, and mesenchymal compartment affect disease development. Early phase trials are informing about pathogenic mechanisms in vivo and reverse translation for observational and randomized trials is allowing hypotheses to be developed and tested. In addition to repurposing already available drugs, these studies are paving the way for the next generation of targeted therapeutics.
Source: Rheumatic Disease Clinics of North America - Category: Rheumatology Authors: J örg H.W. Distler, Gabriela Riemekasten, Christopher P. Denton Source Type: research